Ülke: Birleşik Krallık
Dil: İngilizce
Kaynak: VMD (Veterinary Medicines Directorate)
Propentofylline
Norbrook Laboratories Limited
QC04AD90
Propentofylline
Film-coated tablet
POM-V - Prescription Only Medicine – Veterinarian
Dogs
Cardio Vascular
Expired
2011-11-14
Issued: November 2011 AN: 02607/2008 Page 1 of 4 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Propentofylline 100mg Film Coated Tablets for Dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE: Propentofylline 100.00mg/tablet EXCIPIENTS: Opadry II Blue 85G30552 8.00mg/tablet For a full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Film coated tablet. A light blue oblong tablet, with a central score line on both faces which can be divided into equal halves. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For improvement in dullness, lethargy and overall demeanour in dogs. Is particularly useful in older dogs, where it may increase willingness to exercise and exercise tolerance. 4.3 CONTRAINDICATIONS Do not administer to pregnant bitches or breeding animals. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None 4.5 SPECIAL PRECAUTIONS FOR USE (I) SPECIAL PRECAUTIONS FOR USE IN ANIMALS Specific diseases (e.g. kidney disease) should be treated accordingly. Issued: November 2011 AN: 02607/2008 Page 2 of 4 Consideration should be given to rationalising the medication of dogs already receiving treatment for congestive heart failure or bronchial disease. (II) SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS Care should be taken to avoid accidental ingestion. In the event of accidental ingestion, seek immediate medical advice and show the package leaflet to the doctor. Wash hands after use. 4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS) In the rare event of allergic reactions, treatment with the product should be stopped. 4.7 USE DURING PREGNANCY, LACTATION OR LAY Do not use in pregnant bitches as the product has not been evaluated in these animals. 4.8 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION None known. 4.9 AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE Half tablet per 10kg body weight twice a day. The tablets should Belgenin tamamını okuyun